Zika Virus Therapeutics

Zika Virus Therapeutics

The Zika virus is primarily transmitted through Aedes mosquito bites. It gained attention in 2015-2016 due to its link to birth defects like microcephaly in babies born to infected mothers. Research on Zika virus therapeutics is primarily focused on developing vaccines and antiviral drugs. Vaccine development aimed to create a safe and effective vaccine to prevent Zika virus infection, especially in pregnant women to protect against birth defects. Symptoms include fever, rash, joint pain, and red eyes. Several other factors, such as the rising cases of zika virus, and constant water accumulation are leading drivers of zika virus therapeutics globally. For instance, according to the Pan American Health Organization, in the Region of the Americas, in 2021, a total of 1,430,922 cases of arboviral disease were reported, of those 23,252 (1.6 %) were Zika cases.

The Zika Virus Therapeutics Market is expected to grow at a steady rate of around 5.1% owing to the rising Aedes mosquito population globally. According to the study performed in 2022 in Tanzania, a total of 333 water-holding containers were inspected and 201 (60.4%) had at least an Aedes larvae or pupae. Several factors, including a rising prevalence of mosquito-borne diseases, increasing awareness regarding mosquito-borne diseases, and increased investments in healthcare departments are driving the growth of the market during the forecast period. Apart from this, accelerated treatment efficiency with zika virus therapeutics has resulted in faster treatment procedures and better accuracy which is also driving this market of zika virus therapeutics at a steady rate.

• Based on vaccine type, the market is segmented into inactivated vaccine, subunit vaccine, live-attenuated vaccine, and others. The inactivated vaccine segment held the maximum share in the global market of zika virus therapeutics in 2022 owing to its efficiency in developing immunity in human body against the virus. Inactivated vaccines are created by using a killed version of the virus or bacteria that causes the disease. These vaccines stimulate an immune response without causing the disease itself. By introducing the inactivated pathogen to the body, the immune system learns to recognize and fight the specific virus or bacteria, providing immunity against future infections. Thus, the inactivated vaccine segment held a significant share of the market in 2022.
• Based on end use, the market is segmented into hospitals, clinics, and others. The clinics held a significant share of the market in 2022. Clinics serve as primary healthcare institutions where patients receive an immediate diagnosis, treatment, and ongoing care. They play a pivotal role in the management of patients by providing state-of-the-art medical facilities, specialized expertise, and a multidisciplinary approach to patient care. Rising collaborations and acquisitions are boosting this segment’s growth. Hence, the clinics category is expected to witness higher CAGR during the forecast period.
• For a better understanding of the market adoption of zika virus therapeutics, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is dominating the market in the current scenario of 2022 due to the increasing water pollution, rising Aedes mosquito population, increasing cases of mosquito-borne diseases, and rising number of investments in developing effective zika virus therapeutics. For example, in 2020, according to U.S. Department of Health & Human Services, over 200 types of mosquitoes live in the continental U.S. and U.S. territories; of these 200, about 12 types spread germs that can make people sick. Government organizations are initiating mosquito-borne diseases awareness programs to provide efficient care to patients. Thus, amongst regions, North America held a significant share of the market in 2022.
• Some of the major players operating in the market include Bharat Biotech; GeneOne Life Science; GSK plc.; Hawaii Biotech Inc.; Leidos; INOVIO Pharmaceuticals; LUMOS PHARMA; Cytiva; Takeda Pharmaceutical Company Limited; Cerus Corporation.